Gorham Julie, Taccone Fabio S, Hites Maya
Department of Intensive Care Unit, Hôpital Universitaire de Bruxelles (HUB), 1070 Brussels, Belgium.
Clinic of Infectious Diseases, Hôpital Universitaire de Bruxelles (HUB), 1070 Brussels, Belgium.
Antibiotics (Basel). 2023 Jan 28;12(2):267. doi: 10.3390/antibiotics12020267.
Difficult-to-treat pulmonary infections caused by multidrug-resistant (MDR) pathogens are of great concern because their incidence continues to increase worldwide and they are associated with high morbidity and mortality. Nebulized antibiotics are increasingly being used in this context. The advantages of the administration of a nebulized antibiotic in respiratory tract infections due to MDR include the potential to deliver higher drug concentrations to the site of infection, thus minimizing the systemic adverse effects observed with the use of parenteral or oral antibiotic agents. However, there is an inconsistency between the large amount of experimental evidence supporting the administration of nebulized antibiotics and the paucity of clinical studies confirming the efficacy and safety of these drugs. In this narrative review, we describe the current evidence on the use of nebulized antibiotics for the treatment of severe respiratory infections.
由多重耐药（MDR）病原体引起的难治性肺部感染备受关注，因为其在全球范围内的发病率持续上升，且与高发病率和死亡率相关。在这种情况下，雾化抗生素的使用越来越普遍。对于由MDR引起的呼吸道感染，雾化抗生素给药的优势包括有可能将更高的药物浓度输送到感染部位，从而将使用肠胃外或口服抗生素时观察到的全身不良反应降至最低。然而，大量支持雾化抗生素给药的实验证据与证实这些药物有效性和安全性的临床研究匮乏之间存在不一致。在这篇叙述性综述中，我们描述了目前关于使用雾化抗生素治疗严重呼吸道感染的证据。
